People cycle on GLP‑1s
A majority of people who start GLP‑1 weight‑loss or diabetes drugs later stop them and plan to restart, even though the long‑term health impacts of repeated stopping and starting aren’t yet established. (npr.org) Clinical trial data also show that about 10–15% of users don’t lose weight on GLP‑1s, and researchers are exploring alternative or adjunctive treatments for nonresponders. (ksl.com) Genetic work published in recent reporting links variants in a pair of genes to slightly greater weight loss on GLP‑1s but also to higher rates of vomiting on Zepbound in that cohort. (sciencenews.org)
Glucagon-like peptide-1 drugs help control blood sugar and appetite, but many people who start them stop and later plan to restart. (npr.org) National Public Radio reported on April 15 that a majority of people who begin these medicines later quit, and market researcher Kantar found 74% of people who had lapsed said they were likely or very likely to go back on one. (npr.org) These medicines include semaglutide brands such as Ozempic and Wegovy and tirzepatide brands such as Mounjaro and Zepbound. They mimic gut hormones that slow digestion, lower blood sugar, and reduce hunger, which is why they are used for diabetes and obesity. (npr.org) Researchers do not yet have clear long-term evidence on what repeated stopping and restarting does to health. Earlier withdrawal trials did find that many patients regained weight after stopping, and some cardiometabolic gains moved back toward baseline. (pmc.ncbi.nlm.nih.gov, jamanetwork.com) In the STEP 1 extension trial, people who stopped semaglutide regained about two-thirds of their prior weight loss within a year. In the SURMOUNT-4 trial, people who discontinued tirzepatide regained weight over the next 52 weeks while those who stayed on treatment kept losing. (pmc.ncbi.nlm.nih.gov, patientcareonline.com) Real-world data are messier than trials. Cleveland Clinic said in March that its analysis of nearly 8,000 adults found average weight one year after discontinuation did not rise much overall, in part because many patients restarted the same drug or switched to another obesity treatment. (newsroom.clevelandclinic.org) Not everyone loses meaningful weight on these drugs even while taking them. Clinical trial reporting cited this month put the share of “nonresponders” at about 10% to 15%, meaning they lost less than 5% of body weight. (ksl.com, cbsnews.com) Scientists are now looking for clues to who responds, who does not, and who gets harsher side effects. A Nature study published April 8 found variants in the GLP1R and GIPR genes were linked to slightly greater weight loss on these drugs, and one variant was also linked to more vomiting among people taking Zepbound. (nature.com, sciencenews.org) That leaves doctors and patients making decisions with incomplete evidence: some people stop because of cost, coverage, supply, or side effects, some do not respond much, and many expect to cycle back on later. The next phase of research is not whether these drugs work in general, but who can stay on them, who benefits most, and what happens when treatment becomes intermittent. (npr.org, nature.com, ksl.com)
